drugset / Trial / NCT04660110

Household-level Impact of IPT of Malaria in Schoolchildren

NCT04660110

Phase 3 Unknown 1500 enrolled Makerere University
RandomizedParallel-groupOpen-labelPrevention

Summary

The study will evaluate the household-level impact of IPT for malaria in schoolchildren on malaria transmission, using a randomized trial design. Two schools in Busia district will be randomly selected and randomize to either IPT with dihydroartemisinin piperaquine (DP, IPT arm), or standard of care (no intervention). A single dose/round of IPT with DP (40mg/320mg tabs, Fosun Pharmaceuticals) will be given to the children in the intervention arm. The full dose will be given as oral tablets once a day for 3 consecutive days to all eligible children in the intervention school. Surveys will be conducted in households of 100 randomly selected children in each of the study arms at baseline, one month and three months following the intervention. The target population will include all household members of the selected households.

Timeline

Start
2021-01-28
Primary completion
2021-06-03
Completion
2021-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator ARTENIMOL Small molecule 40 mg Oral
Comparator piperaquine Small molecule 320 mg Oral

Indications